Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,188.72
+31.232.70%
Post-market: 1,190.001.28+0.11%16:28 EDT
Volume:2.30M
Turnover:2.73B
Market Cap:1.12T
PE:39.90
High:1,206.63
Open:1,173.62
Low:1,166.00
Close:1,157.49
52wk High:1,292.65
52wk Low:783.85
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.98
T/O Rate:0.24%
Dividend:6.69
Dividend Rate:0.56%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:33.17
PE(LYR):51.80

Loading ...

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers

TIPRANKS
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
Sep 19

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

All 50 States Sign up for Trump's Medicaid Most-Favored-Nation Plan

Reuters
·
Sep 18

GenScript Joins Lilly TuneLab to Advance AI-Enabled Drug Discovery

AI Industry Frontlines
·
Sep 18

When Weight Loss Isn't the Goal of Taking a GLP-1

Dow Jones
·
Sep 18

Eli Lilly & Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 18

Goldman Sachs Adjusts Eli Lilly Price Target to $1,371 From $1,367, Maintains Buy Rating

MT Newswires Live
·
Sep 17

15 Stocks That Have Grown Dividends the Most - and Nearly All Have Beaten the S&P 500

Dow Jones
·
Sep 17

GenScript Biotech Hits Near 5-Year High on Eli Lilly Collaboration

Reuters
·
Sep 17

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 16